In Phase II Clinical Trials
Development of Effective and Innovative Medicines to Address the needs of Patients and Improve their Health, Longevity and Quality of Life.
Hub Controls
  • Demo Video
  • Private Messages
  • Edit My Profile
  • View/Edit My Portfolio
Email Updates
Search
Message: NEWS - AlphaRx Announces Selection of ARX828, a Novel iNOS inhibitor, for Advanced Preclinical Development
Reply New Message
« Prev Message Back To Forum Go to Threaded View Next Message »
Generic_profile
supernova
Rank: [?]
Mail Room
Points: [?]
21
Rating: [?]
Votes: 0
  • Currently 0.0/5 Stars.
Your Vote:
Please Log In to Vote
Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: NEWS - AlphaRx Announces Selection of ARX828, a Novel iNOS inhibitor, for Advanced Preclinical Development

in response to Re: NEWS - AlphaRx Announces Selection of ARX828, a Novel iNOS inhibitor, for Advanced Preclinical Development by Tutty
posted on Sep 13, 07 04:30PM

They did their homework:

IBD drug market is over US$1B M a year.

Affects >2 million Americans & Europeans

Huge unmet need in inflammatory bowel disease, particularly ulcerative colitis (UC).

Needless to say the RA drug market, over US$4B a year.

Reply New Message
« Prev Message Back To Forum Go to Threaded View Next Message »
New Message

Please login to post a reply

Subscribe to Rss Feed
Executive Address
Alrxsmall
Michael Lee
President
May 18, 2006

 

Michael Lee provides the investor community an update on recent events

View Broadcast

Stock Quote
Open alrx Stock Quote